Skip to content
Screener

Charles River Laboratories CRL Financing Cash Flow

Financing Cash Flow at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
-$919.9M-244%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$247K-34.8%
Sotera Health logo
Sotera HealthSHC
-$2.41M+65.3%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$16.49M+16,926%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$0+100%
Revvity logo
RevvityRVTY
-$88.9M+45.7%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Charles River Laboratories’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:14 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001100682-26-000038
Line itemThree Months Ended / March 28, 2026Three Months Ended / March 29, 2025
Purchase of treasury stock(208,285)(353,132)
Purchase of remaining equity interest of other redeemable noncontrolling interests(19,140)
Other, net(2,000)
Net cash provided by (used in) financing activities347,724(105,325)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash1,2485,265
Net change in cash, cash equivalents, and restricted cash(17,796)26,158
Cash, cash equivalents, and restricted cash, beginning of period215,997205,570
Cash, cash equivalents, and restricted cash, end of period$198,201$231,728

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's financing cash flow?
Charles River Laboratories (CRL) reported financing cash flow of $347.72M in Q1 2026.
How has Charles River Laboratories's financing cash flow changed year-over-year?
Charles River Laboratories's financing cash flow increased by 430.1% year-over-year, from -$105.33M to $347.72M.
What is the long-term trend for Charles River Laboratories's financing cash flow?
Over 2 years (2022 to 2025), Charles River Laboratories's financing cash flow has grown at a 255.8% compound annual growth rate (CAGR), from -$42.4M to -$536.73M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Charles River Laboratories's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude